All Stories

  1. miRNAs as Epigenetic Biomarkers for CTEPH: A case-control study towards personalized medicine
  2. Role of Extracellular Vesicles in Chronic Post-Embolic Pulmonary Hypertension: Data from an Experimental Animal Model and Patients
  3. Regional Disparities and Trends in Venous Thromboembolism Mortality in Spain (1999–2022)
  4. Clinically relevant bleeding according to location of metastases in cancer-associated thrombosis
  5. Relevance of recurrent venous thromboembolism according to location of metastasis in patients with cancer-associated thrombosis. A cohort study
  6. Impact of Residual Vein Venous Thrombosis in Consecutive Patients with Cancer-Associated Thrombosis Treated with Tinzaparin—A Cohort Study
  7. Cost-effectiveness of follow-up algorithms for chronic thromboembolic pulmonary hypertension in pulmonary embolism survivors
  8. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID‐19 vaccine
  9. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study
  10. Optimisation of detecting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism survivors: the InShape IV study
  11. Location of metastasis and complications in patients with venous thromboembolism and cancer: a systematic review
  12. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism
  13. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry
  14. Age and sex differences in pulmonary embolism mortality rates in Spain from 1999 to 2021
  15. Pulmonary embolism: a practical approach to update risk stratification and treatment decisions based on the guidelines
  16. Symptom-related screening programme for early detection of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the SYSPPE study
  17. Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry
  18. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding
  19. The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis
  20. When should we involve interventional radiology in the management of acute pulmonary embolism?
  21. Lack of Funding for Direct-Acting Oral Anticoagulants for the Treatment of Pulmonary Embolism in Spain: Why and Until When
  22. Prospective study to evaluate quality of life in amyotrophic lateral sclerosis
  23. Risk factors for pulmonary embolism in lung cancer patients with lower limb deep venous thrombosis: a case-control study
  24. Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism
  25. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study
  26. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
  27. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study
  28. The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism
  29. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy
  30. Epidemiology of Lung Cancer Mortality in Spain: Updated Information (1982–2021) and Predictions up to 2046
  31. Rate of Recurrence After Discontinuing Anticoagulation Therapy in Patients With COVID-19–Associated Venous Thromboembolism
  32. Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
  33. Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism
  34. Low-molecular-weight heparin beyond 12 months in patients with cancer-associated thrombosis
  35. COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment
  36. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism
  37. Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry
  38. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
  39. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
  40. Low‐dose apixaban in extended treatment of cancer‐associated thrombosis: Less is more?
  41. Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model
  42. Mechanical Behavior of Calcium Sulphate Modified with Citric Acid and with Added Carbon Fibers
  43. ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly
  44. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
  45. Major bleeding in patients with pulmonary embolism presenting with syncope
  46. Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial
  47. Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
  48. Venous thromboembolism in amyotrophic lateral sclerosis. A prospective quasi-experimental study
  49. Consenso multidisciplinar para el manejo de la tromboembolia de pulmón
  50. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism
  51. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on At...
  52. Comment on “Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes: From the COMMAND VTE Registry”
  53. The immune-neuroendocrine system in COVID-19, advanced age and rheumatic diseases
  54. PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19
  55. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism
  56. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation
  57. Analysis of Additives in Gypsum Coatings Based on Melamine, Polycarbonate Salts, Polycarboxylate, and Polycarboxylic Acids
  58. First Detection and Genome Sequencing of SARS-CoV-2 Lambda (C.37) Variant in Symptomatic Domestic Cats in Lima, Peru
  59. Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism
  60. WITHDRAWN: Multidisciplinary consensus for the management of pulmonary thromboembolism
  61. Spanish consensus for the management of pulmonary thromboembolism
  62. Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism
  63. Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐ or therapeutic doses of thromboprophylaxis
  64. Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
  65. Trombosis sintomática de la vena ácigos: caso clínico y revisión de la literatura
  66. Timing and characteristics of venous thromboembolism after noncancer surgery
  67. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
  68. Análisis de las indicaciones y complicaciones de los pacientes con enfermedad tromboembólica venosa a los que se ha colocado filtro de vena cava inferior
  69. Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis
  70. Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before–After Study (CortiCOVID Study)
  71. Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS—CAT Study
  72. Deep vein thrombosis and brain metastases. Case report and systematic review
  73. Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study
  74. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study
  75. Incidental vs. suspected PE in patients with cancer.
  76. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry
  77. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
  78. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts
  79. Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors
  80. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
  81. Documento de consenso de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) para el seguimiento clínico post-COVID-19
  82. Venous thromboembolism in solid-organ transplant recipients: findings from the RIETE registry
  83. Prognostic Significance of Incidental Deep Vein Thrombosis in Patients with Cancer Presenting with Incidental Pulmonary Embolism
  84. Correlation between short-term air pollution exposure and unprovoked lung embolism. Prospective observational (Contamina-TEP Group)
  85. Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future
  86. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score
  87. Differential biomarker profiles between unprovoked venous thromboembolism and cancer
  88. Screening for occult cancer: where are we in 2020?
  89. Comments on the 2019 ESC guidelines on acute pulmonary embolism
  90. Comentarios a la guía ESC 2019 sobre embolia pulmonar aguda
  91. Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi
  92. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry
  93. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
  94. Systolic blood pressure and mortality in acute symptomatic pulmonary embolism
  95. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project
  96. A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study
  97. Riesgo de recurrencia tras retirada de la anticoagulación en pacientes con enfermedad tromboembólica venosa no provocada: validación externa del nomograma de Viena y del modelo predictivo DASH
  98. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years
  99. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  100. Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry
  101. El dilema de la reducción de tratamiento en pacientes con asma moderado-grave controlados
  102. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
  103. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry
  104. Outcome of pulmonary hypertension associated with respiratory disease
  105. Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin
  106. Extended treatment of cancer-associated thrombosis
  107. Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry
  108. D‐dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry
  109. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry
  110. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study
  111. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  112. Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database
  113. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  114. Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis
  115. Venous thromboembolism in young adults: Findings from the RIETE registry
  116. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
  117. Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry
  118. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis
  119. Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
  120. Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
  121. Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis
  122. Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry
  123. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
  124. Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism
  125. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
  126. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry
  127. Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry
  128. Towards a precision medicine in venous thromboembolism associated to lung cancer
  129. Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos
  130. Management appropriateness and outcomes of patients with acute pulmonary embolism
  131. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism
  132. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis
  133. Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism
  134. Awareness and understanding of venous thromboembolism in patients with cancer: data on 100 unselected cancer outpatients
  135. Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
  136. Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy
  137. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism
  138. Prevalence of dual clarithromycin and metronidazole resistance in Helicobacter pylori estimated by molecular methods in Santiago, Chile
  139. Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score
  140. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
  141. Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
  142. Características clínicas y pronóstico de la tromboembolia pulmonar secundaria al síndrome de clase turista
  143. Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome
  144. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism
  145. Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants
  146. Correction:Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis
  147. Sex Differences in Patients With Occult Cancer After Venous Thromboembolism
  148. Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up
  149. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis
  150. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism
  151. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation
  152. Response
  153. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
  154. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE
  155. Calidad de vida en pacientes diagnosticados de embolia de pulmón aguda sintomática
  156. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry
  157. Predictors of active cancer thromboembolic outcomes
  158. Noninvasive ventilation during the weaning process in chronically critically ill patients
  159. Unusual site thrombosis: splanchnic vein thrombosis, management in noncirrothic
  160. Search predictive factors of recurrence in venous thromboembolic disease associated with cancer after withdrawal of the anticoagulation. HISPALIS study
  161. Occult cancer in patients with acute venous thromboembolism: Why, when and where to investigate
  162. Treatment of venous thromboembolism in cancer patients with tinzaparin beyond 6 months. TiCAT study
  163. DVT Management and Outcome Trends, 2001 to 2014
  164. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units
  165. Analysis of environmental risk factors for pulmonary embolism: A case-crossover study (2001–2013)
  166. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective
  167. Trends in the Management and Outcomes of Acute Pulmonary Embolism
  168. Discharge Planning of Neuromuscular Patients with Noninvasive Mechanical Ventilation After Difficult Weaning from Invasive Mechanical Ventilation: From ICU to Home Care
  169. Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry
  170. High correlation between 2 flow cytometry platforms in the microparticles analysis using a new calibrated beads strategy
  171. Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
  172. Respiratory intermediate care units: Noninvasive ventilation for severe acidotic patients
  173. Factors associated with mortality and survival in venous thromboembolism and hidden or concurrent cancer
  174. Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients
  175. The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism
  176. Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
  177. Corrigendum to ‘Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients’ [Thrombosis Research 134 (2014) 617–621]
  178. A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis
  179. Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy
  180. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity
  181. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism
  182. Venous thromboembolism in patients immobilised at home
  183. Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate
  184. Fondaparinux in the initial and long-term treatment of venous thromboembolism
  185. Gender differences in cancer patients with acute venous thromboembolism
  186. Lights and shadows of non-invasive mechanical ventilation for chronic obstructive pulmonary disease (COPD) exacerbations
  187. A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs
  188. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy
  189. Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients
  190. Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism
  191. C0396: Thrombophilia in Thrombosis and Cancer
  192. C0211: Prevalence of Metabolic Syndrome and All-Causes Mortality in Patients with Acute Symptomatic Venous Thromboembolism (VTE)
  193. C0246: Quality of Life in Acute Symptomatic Pulmonary Embolism and Low-Risk Prognosis
  194. C0306: Rivaroxaban for Treatment of Venous Thromboembolism. A Real-Life Perspective in 103 Patients
  195. D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer
  196. Pulmonary Embolism and Concomitant Paradoxical Embolism. A Case Report
  197. Tromboembolismo pulmonar y embolia paradójica concomitante. A propósito de un caso
  198. Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar
  199. La escala predictiva de Khorana en pacientes con enfermedad tromboembólica venosa y cáncer
  200. Validación de 2 escalas clínicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática
  201. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism
  202. Normativa sobre el manejo de las complicaciones respiratorias de los pacientes con enfermedad neuromuscular
  203. Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism
  204. Hipertensión pulmonar tromboembólica crónica
  205. Clinical Manifestations of Sarcoidosis
  206. Platelet count and outcome in patients with acute venous thromboembolism
  207. Análisis de 3 métodos para determinar el dímero D en pacientes con sospecha de trombosis venosa profunda
  208. Control ambulatorio de los pacientes con trombosis venosa profunda y cáncer: estudio de seguridad, costes e impacto presupuestario
  209. Chronic Thromboembolic Pulmonary Hypertension Due to Upper-Extremity Deep Vein Thrombosis Caused Thoracic Outlet Syndrome
  210. Hipertensión pulmonar tromboembólica crónica debida a trombosis venosa profunda de miembro superior por síndrome del desfiladero torácico
  211. Updated Guidelines for the Treatment of Pulmonary Sarcoidosis
  212. Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis
  213. Malformaciones de la vena cava inferior como causa de trombosis venosa profunda. A propósito de dos casos
  214. Dyslipidemia as a long-term marker for survival in pulmonary embolism
  215. Lung cancer mortality in Spain: estimating the future burden to the year 2028
  216. Gender differences in lung cancer mortality trends in Andalusia 1975–2008: a joinpoint regression analysis
  217. Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism
  218. Right Atrium Mass in a 28-Year-Old Patient with Pulmonary Embolism Taking Contraceptives
  219. Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia
  220. Testing for occult cancer in patients with pulmonary embolism: Results from a screening program and a two-year follow-up survey
  221. Hallazgos en el lavado broncoalveolar de pacientes con enfermedad pulmonar intersticial difusa. Estudio de una cohorte prospectiva de 562 pacientes
  222. Hemorragia pulmonar por capilaritis pauciinmunitaria aislada con anticuerpos anticitoplasma de los neutrófilos negativos
  223. Síndrome hepatopulmonar en pacientes con hepatopatía avanzada: estudio de 24 casos
  224. Infección por Aspergillus terreus en pacientes con EPOC en tratamiento con corticoides. A propósito de tres casos
  225. Hemorragia digestiva baja asociada a celecoxib